Abstract

SICKLE CELL DISEASE: TREATMENT ON MOLECULAR LEVEL

Sarika Gorakhanath Shinde* and Preetam Lala Nikam

Abstract

Sickle cell disease is one of most common hereditary disorder that affects millions of people over the world wide. It is autosomal dominant. It is a monogenic disorder caused by an point mutation in B chain of haemolysis that causes polymerization of deoxygenated Sickle haemoglobin. (HbS). SCD the most common problem analogous with SCD is Vaso- occlusion and haemolysis. In spite of latest advances in understandind this disorder a molecular level, few therapeutic Strategies are available. Hydroxyurea is recently approved by the USFDA for the SCD. But this drug has crucial side effects and ineffectiveness in some patients. So, however, new therapeutic strategies are under research to discover new drug to treat SCD.

Keywords: Sickle cell Disease. Haemoglobinopathy gamma globin, Fetal Hemoglobin drug discovery.